PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Tyrogenex, a privately held company focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, today announced the release of one abstract for X-82 to be presented as a poster during the 2015 American Society for Clinical Oncology (ASCO) annual meeting held in Chicago May 29 through June 2.
X-82 in combination with docetaxel to measure change in vascular parameters and proliferation:
Title: Pharmacodynamic study using FLT PET/CT in advanced
solid malignancies treated with a sequential combination of X-82 and
docetaxel
Poster Session: Saturday, May 30, 8 a.m. –
11:30 a.m., Developmental Therapeutics—Clinical Pharmacology and
Experimental Therapeutics
Abstract Number: TPS2601
Poster
Board Number: 317a
Location: S Hall A
Presenter:
Justine Bruce, M.D., Carbone Cancer Center, University of Wisconsin,
Madison, WI
About Tyrogenex
Tyrogenex is
developing X-82, as a targeted therapeutic for ophthalmological diseases
and solid tumors. Preliminary data from a phase 1 single agent study
show that X-82 is well tolerated and did not exhibit any dose-limiting
toxicity during the study.
In oncology, VEGFR tyrosine kinase inhibitors, such as X-82, typically have demonstrated benefit in a variety of cancers though dosage, and use of this class in combination with other therapies, has been limited by side effects. Phase 1 data show that X-82 could a have a significantly lower toxicity profile, which may make it an ideal candidate for combination therapy.
For ophthalmology, the company has initiated a phase 2 study known as “APEX,” for wet AMD in Previously treated Eylea patients with X-82. The study is designed to evaluate the safety and efficacy of X-82 in the prevention of vision loss due to wet AMD. A phase 1 study showed X-82 was able to maintain or improve vision in all subjects who received the drug for the six-month study duration and most subjects did not require any rescue injections during that time. There were no dose-limiting toxicities encountered during the study.
